cell

(redirected from hairy cell)
Also found in: Dictionary, Thesaurus, Medical, Legal, Encyclopedia.

cell

an independent team of operatives who work together in a CELLULAR MANUFACTURING production environment.
References in periodicals archive ?
The "Global Hairy Cell Leukemia Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
Histopathological lesions of the liver in hairy cell leukemia: a report of 14 cases.
AstraZeneca, a UK-based pharmaceutical company, and MedImmune, its global biologics research and development arm, announced on Friday that the US Food and Drug Administration (FDA) has approved Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
AstraZeneca Plc (LON:AZ), a global, science-led biopharmaceutical company, and MedImmune, the company's global biologics research and development arm, announced on Friday the approval by the US Food and Drug Administration (FDA) of Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Bone marrow biopsy showed nodular and interstitial proliferation of small, partially atypical T lymphocytic cells positive for CD2, CD3, CD5, CD8, granzyme and TIA and negative for hairy cell markers, CD10, MUM 1, bcl 1, CD4 and CD56.
Hemophagocytic syndrome, tuberculosis, AML, hairy cell leukaemia, multiple myeloma, myelofibrosis and druginduced pancytopenia were rare causes of pancytopenia in the study conducted by Khunger JM et al and Tilak et al.
Moxetumomab pasudotox is an investigational anti-CD22 recombinant immunotoxin and a potential new medicine for the treatment of adult patients with hairy cell leukemia (HCL) who have received at least two prior lines of therapy.
[12], outer hairy cell number was preserved in rats using lycopene in cisplatin-induced ototoxicity, and higher DP-gram values were present in DPOAE measurements when compared with cisplatin group not undergoing treatment.
Only three cases occurred in the absence of preexisting tissue disruption: one patient was on immunosuppressive agents and had exposure to chickens [4], the second had hairy cell leukemia [5], and the third was immunocompetent but had recently sustained a facial bite from a raccoon [6].
Hairy cell leukemia (HCL) is an uncommon haematological malignancy characterized by clonal disease of mature B lymphocytes with fine villous cytoplasmic projections (hence the name hairy cells) found in the bone marrow and peripheral blood.
We observed hairy cell damage in the cochlea and cochlear degeneration mostly in the gentamicin group.